SAB Biotherapeutics (SABS) filed a registration statement on Tuesday with the US Securities and Exchange Commission for the sale of up to $300 million of securities over time.
The securities cover common and preferred stocks, debt securities, warrants, rights, and units.
Net proceeds will be used for the development and commercialization of product candidates and general corporate purposes.
Price: 3.54, Change: -0.11, Percent Change: -3.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.